glp-1 chart The trend: What the real-world data reveals Mapping the effectiveness and risks
Description
Clinical uses Type 2 Diabetes Mellitus (T2DM) : Effective in lowering blood glucose without a significant risk of hypoglycemia
doi:10.1111/dom.15769 24
A retrospective medical database analysis of T2D patients (n = 39,275) treated with exenatide or other glucose-lowering therapies (n = 381,218) indicated that the GLP-1 agonist might reduce in 19% the incidence of MACCE and in 12% cardiovascular hospitalizations [71]
Markovic TP, Proietto J, Dixon JB, Rigas G, Deed G, Hamdorf JM, et al
G., Remy, P., Giordana, C., et al
Lori Martin
